Cystic fibrosis–related diabetes
| Cystic fibrosis–related diabetes | |
|---|---|
| Synonyms | CFRD |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Increased thirst, frequent urination, unexplained weight loss, fatigue |
| Complications | Lung infections, nutritional deficiencies, microvascular complications |
| Onset | Typically in adolescence or adulthood |
| Duration | Chronic |
| Types | N/A |
| Causes | Cystic fibrosis, insulin deficiency |
| Risks | Cystic fibrosis, family history of diabetes |
| Diagnosis | Oral glucose tolerance test, fasting blood glucose, HbA1c |
| Differential diagnosis | Type 1 diabetes, Type 2 diabetes |
| Prevention | Regular monitoring, nutritional management |
| Treatment | Insulin therapy, dietary management, exercise |
| Medication | Insulin |
| Prognosis | Variable, depends on lung function and nutritional status |
| Frequency | Affects 20-50% of adults with cystic fibrosis |
| Deaths | N/A |
Cystic Fibrosis-Related Diabetes (CFRD) is a unique type of diabetes that is found in individuals with Cystic Fibrosis (CF). CFRD is considered the most common complication of CF, affecting approximately 20% of adolescents and 40-50% of adults with the disease. Unlike other forms of diabetes, CFRD presents a mix of features from both Type 1 diabetes and Type 2 diabetes, making its management particularly challenging.
Pathophysiology[edit]
The pathophysiology of CFRD is complex and not entirely understood. It involves both insulin deficiency due to the destruction of the pancreas and insulin resistance. In CF, thick mucus blocks the ducts of the pancreas, preventing the release of insulin and leading to chronic inflammation and fibrosis. This damage to the pancreas results in decreased insulin production, characteristic of Type 1 diabetes. Additionally, the chronic inflammation seen in CF can lead to insulin resistance, a hallmark of Type 2 diabetes.
Diagnosis[edit]
Diagnosis of CFRD can be challenging as the symptoms can be subtle and may overlap with those of CF itself. The Oral Glucose Tolerance Test (OGTT) is considered the gold standard for diagnosing CFRD. According to the Cystic Fibrosis Foundation guidelines, it is recommended that all individuals with CF undergo annual screening for CFRD starting by age 10.
Symptoms[edit]
Symptoms of CFRD may include, but are not limited to, unexplained weight loss, increased thirst, increased urination, and fatigue. These symptoms often mimic those of classic diabetes but can be overlooked in CF patients due to the overlap with symptoms of their underlying lung disease.
Treatment[edit]
The treatment of CFRD focuses on maintaining optimal blood glucose levels without compromising nutritional status, which is crucial in CF management. Insulin therapy is the cornerstone of CFRD treatment, as oral diabetes medications are often ineffective due to the unique pathophysiology of the disease. Nutritional management also plays a critical role, with a focus on maintaining a high-calorie diet to counteract the malabsorption and increased energy needs associated with CF.
Impact on Cystic Fibrosis[edit]
The development of CFRD has significant implications for individuals with CF. Research has shown that CFRD is associated with a decline in lung function, increased frequency of pulmonary exacerbations, and reduced survival. Therefore, early detection and aggressive management of CFRD are essential to improve outcomes in CF patients.
Conclusion[edit]
CFRD is a complex condition requiring a multidisciplinary approach for its management. Ongoing research is essential to better understand the pathophysiology of CFRD and to develop more effective treatments. Early diagnosis and comprehensive management are key to improving the quality of life and prognosis for individuals with CFRD.
NIH genetic and rare disease info[edit]
Cystic fibrosis–related diabetes is a rare disease.
| Rare and genetic diseases | ||||||
|---|---|---|---|---|---|---|
|
Rare diseases - Cystic fibrosis–related diabetes
|
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian